ADVFN US – Market Content Editor
-
Goldman Sachs slips despite first-quarter earnings beat
Goldman Sachs Group (NYSE:GS) reported stronger-than-expected first-quarter results, but its shares dropped 3.8% following the announcement. The bank posted earnings per share of $17.55 for the period ending March 31, comfortably ahead of the $16.47 consensus forecast. Revenue came in at $17.23 billion, also topping estimates of $16.95 billion and rising 14% from $15.09 billion…
-
Commvault appoints Gary Merrill as CFO, Geoff Haydon to lead customer operations
Commvault (NASDAQ:CVLT) has announced two senior leadership changes effective immediately, naming Gary Merrill as Chief Financial Officer and Geoff Haydon as President of Customer and Field Operations. Both will report directly to CEO Sanjay Mirchandani. Merrill returns to the CFO position, a role he previously held from 2022 to 2024. Over the past two years,…
-
Allogene shares jump on encouraging ALPHA3 trial update
Allogene Therapeutics (NASDAQ:ALLO) surged 36% on Monday after releasing positive interim data from its pivotal ALPHA3 study, showing that cemacabtagene ansegedleucel (cema-cel) delivered significantly higher minimal residual disease (MRD) clearance rates compared with observation. The interim futility analysis revealed MRD clearance of 58.3% in the cema-cel arm versus 16.7% in the observation group, representing a…
-
Strategy adds nearly 14,000 bitcoin after $1bn preferred stock sale
Strategy Inc (NASDAQ:MSTR) raised $1.00 billion through the sale of 10.03 million shares of its Variable Rate Series A Perpetual Stretch Preferred Stock between April 6 and April 12, 2026, according to a regulatory filing. The company reported net proceeds of $1.00 billion from the transaction, with $21.64 billion still available under its at-the-market (ATM)…
-
Spyre Therapeutics shares jump after positive ulcerative colitis trial data
Spyre Therapeutics (NASDAQ:SYRE) shares climbed 25% on Monday after the company reported that its investigational therapy SPY001 achieved its primary endpoint in a Phase 2 study targeting ulcerative colitis. The biotech group released 12-week results from Part A of its SKYLINE trial, showing that SPY001 delivered a statistically significant 9.2-point reduction in the Robarts Histopathology…
-
3D Systems unveils new dual-laser printer and factory software at RAPID + TCT
3D Systems Corporation (NYSE:DDD) introduced its latest SLA 825 Dual stereolithography system alongside the AddiTrak software platform at the RAPID + TCT 2026 event in Boston. The SLA 825 Dual offers a 22% increase in build volume and delivers up to 25% faster production speeds compared to earlier models. It is aimed at high-throughput manufacturing…
-
AbbVie ends CollPlant deal and slashes workforce to cut costs
CollPlant Biotechnologies (NASDAQ:CLGN) said its collaboration with AbbVie (NYSE:ABBV) has been terminated, prompting the company to implement cost-cutting measures including a reduction of around 50% of its workforce. The termination was initiated by Allergan Industrie SAS, an AbbVie subsidiary, which exercised its contractual right to exit the agreement with 60 days’ notice. The partnership, established…
-
Fastenal shares drop despite meeting estimates as growth outlook softens
Fastenal Company (NASDAQ:FAST) reported first-quarter results in line with analyst expectations on Monday, but its shares slid around 6% in pre-market trading as investors reacted to signs of slowing growth and margin pressures. The industrial supplies distributor posted adjusted earnings per share of $0.30 on revenue of $2.2 billion, both matching consensus forecasts. Sales rose…
-
IDEAYA shares soar on positive late-stage melanoma trial data
IDEAYA Biosciences (NASDAQ:IDYA) stock surged 27% on Monday after the company reported encouraging topline results from its Phase 2/3 registrational study evaluating darovasertib in combination with crizotinib for first-line treatment of metastatic uveal melanoma. The OptimUM-02 study achieved its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS). Patients receiving the combination…
-
Sandisk shares jump after Nasdaq-100 addition
Sandisk Corporation (NASDAQ:SNDK) shares climbed around 4% on Monday after the company was confirmed for inclusion in the Nasdaq-100 Index. Nasdaq said Sandisk will join the benchmark index ahead of the market open on April 20, 2026, replacing Atlassian Corporation (NASDAQ:TEAM). Being added to the Nasdaq-100 often boosts demand for a stock, as funds and…